Spirepoint Private Client LLC Has $9.37 Million Position in Gilead Sciences, Inc. $GILD

Key Points

• Spirepoint Private Client LLC raised its stake in Gilead by 16.4%, adding 10,780 shares in Q4 to hold 76,346 shares valued at approximately $9.37 million.
• Gilead beat quarterly estimates with EPS of $1.86 (vs. $1.83) and revenue of $7.93B (up 4.7% YoY), set FY2026 guidance of 8.45–8.85 EPS, and raised its quarterly dividend to $0.82 (2.3% yield).
• The company is pivoting into oncology—agreeing to acquire Tubulis for up to $5B, licensing KT‑200 from Kymera and expanding collaborations—which has driven several price‑target upgrades but also raised execution/integration risk concerns.

Spirepoint Private Client LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 76,346 shares of the biopharmaceutical company's stock after purchasing an additional 10,780 shares during the quarter. Spirepoint Private Client LLC's holdings in Gilead Sciences were worth $9,371,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in GILD. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the 3rd quarter valued at $26,000. Financial Consulate Inc. raised its stake in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 109 shares during the period. MTM Investment Management LLC increased its stake in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 176 shares during the last quarter. BOCHK Asset Management Ltd acquired a new position in shares of Gilead Sciences in the fourth quarter worth $31,000. Finally, Millstone Evans Group LLC increased its stake in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 118 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.4%

Shares of NASDAQ:GILD opened at $142.09 on Friday. The stock has a market capitalization of $176.36 billion, a PE ratio of 20.99, a P/E/G ratio of 1.88 and a beta of 0.39. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The firm has a fifty day moving average price of $145.19 and a 200 day moving average price of $130.18. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analysts' expectations of $7.68 billion. During the same period in the prior year, the company posted $1.90 earnings per share. Gilead Sciences's revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences's dividend payout ratio is currently 48.45%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the insider directly owned 131,779 shares in the company, valued at $19,006,485.17. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares of the company's stock, valued at $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 299,280 shares of company stock valued at $42,820,550 over the last three months. 0.30% of the stock is currently owned by insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion, strengthening its ADC pipeline and signaling a strategic push into oncology that investors view as growth diversification beyond Gilead’s legacy franchises. Gilead Expands Oncology Pipeline With $5B Tubulis Deal
• Positive Sentiment: Gilead exercised an option to license KT‑200 from Kymera, triggering a $45M milestone; KT‑200 is a first‑in‑class oral CDK2 molecular‑glue degrader, adding a novel targeted modality to Gilead’s pipeline. Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
• Positive Sentiment: Gilead expanded a multi‑year collaboration with Tempus to apply RWE/AI to oncology R&D, which could accelerate clinical development and improve trial design across its growing cancer portfolio. Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
• Positive Sentiment: Gilead exercised the first option from its Cartography collaboration to license a novel oncology target, validating external discovery platforms and expanding its target discovery engine. Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
• Positive Sentiment: Truist raised its price target to $155 (from $152) and kept a Buy rating, citing easing sector regulatory/policy headwinds and increased deal activity that could sustain momentum. Gilead price target raised to $155 from $152 at Truist
• Positive Sentiment: Analyst coverage includes bullish forecasts (e.g., RBC projecting strong upside and some firms reiterating Buy/Outperform), supporting investor confidence in Gilead’s longer‑term strategic pivot. Royal Bank Of Canada Forecasts Strong Price Appreciation for Gilead Sciences NASDAQ: GILD Stock
• Neutral Sentiment: Gilead’s earnings history and recent beats keep expectations elevated ahead of the next report, which can support sentiment but also sets a higher bar for future surprises. Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Short‑term market commentary notes the stock has recently advanced but still lags broader market moves; trading volume today is below average, so price moves may be sensitive to news flow. Gilead Sciences Inc. stock rises Wednesday, still underperforms market
• Negative Sentiment: Some analysts warn about execution risk from rapid deal activity and integration challenges; Goldman Sachs maintained a Hold citing that risk, which tempers upside until pipeline synergies are proven. Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $170.00 price target on shares of Gilead Sciences in a research note on Monday, February 23rd. Scotiabank upped their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, February 11th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a "sector perform" rating in a research note on Tuesday. Cantor Fitzgerald upped their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $157.81.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.